Boston Scientific Reports Strong Performance Data for SYNERGY Stent System, Shows Target Lesion Revascularization Remains Low

By: via Benzinga
Boston Scientific Corporation (NYSE: BSX) reported positive three-year follow-up data for the EVOLVE clinical trial, comparing the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.